缺氧微环境下PCDH20/IL-6/STAT3信号轴通过增强肝癌细胞干性促进TACE术后复发的机制研究
批准号:
82102161
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
吴艳琴
依托单位:
学科分类:
介入医学与工程
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
吴艳琴
中文摘要
缺氧微环境下肿瘤细胞干性增强是肝癌TACE术后复发的重要原因。IL-6/STAT3信号通路与肿瘤细胞干性密切相关。申请人前期发现HCC患者TACE术后IL-6水平明显升高,是预后不良的独立危险因素。通过组织芯片及生信工具发现PCDH20极有可能是IL-6/STAT3通路的调控靶点。进一步的细胞实验表明,缺氧环境下PCDH20表达下调,而过表达PCDH20可抑制IL-6/STAT3号通路降低肝癌细胞干性。因此,我们提出:缺氧环境下PCDH20/IL-6/STAT3信号轴通过增强肝癌细胞干性促进TACE术后复发,但具体分子机制尚未阐明。鉴于此,本研究拟从体内外水平探讨TACE术后缺氧微环境下PCDH20/IL-6/STAT3介导肝癌细胞干性促进肿瘤复发的具体分子机制,并进一步分析上述关键基因表达水平与TACE临床疗效的关系。本研究有望从干细胞层面为提高TACE远期疗效提供新的思路与策略。
英文摘要
Enhanced stemness of hepatoma cells under hypoxia microenvironment is the main reason for the recurrence of hepatocellular carcinoma (HCC) after TACE. IL-6 / STAT3 signaling pathway plays an important role in regulating the stemness of hepatoma cells. Our previous studies found that IL-6 level was significantly increased after TACE, which is an independent risk factor for poor prognosis. We found that Protocadherin 20 (PCDH20) is very likely to a regulator of the IL-6/STAT3 signaling pathway via tissue chip and bio-information analysis tools. Cell function experiments furtherly showed that PCDH20 was down-regulated under hypoxia microenvironment. Overexpression of PCDH20 can reduce the stemness of HCC cells by down-regulating IL-6 / STAT3 signaling pathway. Therefore, it is reasonable to speculate that PCDH20 / IL-6 / STAT3 signal axis promotes the recurrence of HCC after TACE by enhancing the stemness of HCC cells under hypoxic environment, but its molecular regulatory mechanism has not been elucidated. In view of this, this study intends to explore the specific regulatory mechanism of PCDH20/ IL-6 / STAT3 pathway on the stemness of hepatoma cells under hypoxia microenvironment in vivo and in vitro, and furtherly analyze the relationship between the expression level of these key genes and the clinical efficacy of TACE. This study is expected to provide new ideas and strategies for improving the long-term efficacy of TACE from the stem cell level.
本研究聚焦于PCDH20在肝细胞癌(HCC)中的作用,系统探讨其通过调控IL-6/STAT3信号轴影响肝癌细胞干性及化疗敏感性的机制,并评估其在TACE(经肝动脉化疗栓塞术)治疗中的潜在应用价值。研究发现,TACE术后缺氧微环境可诱导IL-6表达上调,激活STAT3信号通路,进而促进肝癌细胞干性和耐药性,而PCDH20可通过抑制Smad3磷酸化,降低IL-6/STAT3信号通路活性,从而增强化疗敏感性并降低肝癌细胞干性。在体外研究中,我们构建了稳定过表达PCDH20的SMMC-7721肝癌细胞株,并发现其可显著抑制细胞增殖、迁移和侵袭,同时增强奥沙利铂诱导的细胞毒性。此外,PCDH20可下调MDR1的表达,减少药物外排,提高化疗药物在肝癌细胞内的蓄积,进一步增强其对化疗的敏感性。在缺氧环境下,过表达PCDH20可显著降低CD133、CD44、NANOG等干性相关基因的表达,减少肝癌干性细胞比例。在动物实验中,我们成功建立了大鼠原位肝癌TACE模型,并通过经肝动脉注入AAV-PCDH20的方法,发现其可显著抑制肿瘤生长,显著提高TACE疗效。免疫组化及Western blot分析进一步证实,PCDH20在HCC患者的肿瘤组织中低表达,并与IL-6及p-STAT3的表达呈负相关,进一步支持其在HCC进展中的抑癌作用。. 研究期间,项目组成员依托本项目在 Journal of Cancer Research and Clinical Oncology 等期刊发表 SCI 论文 4 篇,并多次在国内外学术会议上进行壁报交流及口头报告。团队培养博士研究生 1 名,并获得 “中山大学附属第一医院柯麟新苗人才” 项目资助,赴美国梅奥医学中心进一步深造。项目负责人及核心成员凭借研究成果顺利晋升,团队整体科研实力得到进一步提升。. 本研究首次系统性阐述了PCDH20在肝癌TACE治疗中的重要作用,为提高TACE疗效、优化肝癌个体化治疗方案提供了新的理论依据,并为后续临床转化研究奠定了基础。
国内基金
海外基金